Pieris Pharmaceuticals
Boston
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $160.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2023)
- Ticker: otcpink:PIRS
- Website: pieris.com
- Phone: +118572468998
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pieris-pharmaceuticals-2230201 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.